JPMorgan Chase & Co. Buys 1,474,560 Shares of Nkarta, Inc. (NASDAQ:NKTX)

JPMorgan Chase & Co. lifted its position in Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 138.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,537,922 shares of the company's stock after purchasing an additional 1,474,560 shares during the quarter. JPMorgan Chase & Co. owned 3.60% of Nkarta worth $6,319,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the stock. Geode Capital Management LLC raised its stake in Nkarta by 3.0% during the third quarter. Geode Capital Management LLC now owns 1,171,026 shares of the company's stock worth $5,294,000 after acquiring an additional 33,927 shares in the last quarter. State Street Corp raised its stake in Nkarta by 1.4% during the third quarter. State Street Corp now owns 1,098,062 shares of the company's stock worth $4,963,000 after acquiring an additional 15,569 shares in the last quarter. Barclays PLC raised its stake in Nkarta by 161.4% during the third quarter. Barclays PLC now owns 232,566 shares of the company's stock worth $1,051,000 after acquiring an additional 143,608 shares in the last quarter. Wellington Management Group LLP raised its stake in Nkarta by 24.8% during the third quarter. Wellington Management Group LLP now owns 216,341 shares of the company's stock worth $978,000 after acquiring an additional 43,035 shares in the last quarter. Finally, FMR LLC raised its stake in Nkarta by 97.1% during the third quarter. FMR LLC now owns 133,149 shares of the company's stock worth $602,000 after acquiring an additional 65,600 shares in the last quarter. 80.54% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have issued reports on NKTX shares. Needham & Company LLC reiterated a "buy" rating and set a $11.00 price objective on shares of Nkarta in a research note on Wednesday, April 9th. Stifel Nicolaus lowered their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a research note on Thursday, March 27th. Finally, HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Nkarta in a research note on Thursday, March 27th. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $14.86.

Nkarta Trading Down 0.9 %

Nkarta stock traded down $0.02 during mid-day trading on Wednesday, hitting $2.20. The stock had a trading volume of 200,804 shares, compared to its average volume of 1,094,983. The stock has a 50-day simple moving average of $1.77 and a two-hundred day simple moving average of $2.43. The stock has a market capitalization of $156.07 million, a PE ratio of -1.17 and a beta of 0.83. Nkarta, Inc. has a 12 month low of $1.31 and a 12 month high of $8.33.

Nkarta (NASDAQ:NKTX - Get Free Report) last posted its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.41) by $0.06. Sell-side analysts expect that Nkarta, Inc. will post -1.7 earnings per share for the current fiscal year.

Nkarta Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.